Welcome to our dedicated page for Vyant Bio news (Ticker: VYNT), a resource for investors and traders seeking the latest updates and insights on Vyant Bio stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vyant Bio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vyant Bio's position in the market.
Vyant Bio, Inc. (Nasdaq: VYNT) has announced that CEO Jay Roberts will present at A.G.P.’s Virtual MedTech Summer Conference on July 29, 2021. He will share insights into the Company’s updated business strategy and progress following the merger with StemoniX, Inc. The presentation will cover Vyant Bio's efforts in drug discovery, leveraging novel human-derived biology and proprietary data science technologies. Additionally, one-on-one meetings will be available for conference attendees to engage with Vyant Bio representatives.
Vyant Bio (Nasdaq: VYNT) announced the issuance of US Patent No. 11054408 for a novel approach in drug discovery utilizing human-induced pluripotent stem cells (iPSCs). This patent, assigned to its subsidiary StemoniX, covers a high throughput assay for CNS cells, enhancing drug screening accuracy. It emphasizes the benefits of iPSCs over traditional methods, facilitating better disease modeling and potential new drug targets. The patent represents the third granted to StemoniX, with additional applications pending globally.
Vyant Bio (Nasdaq: VYNT), formerly Cancer Genetics, reported key updates on May 17, 2021, following its merger with StemoniX. The company raised $27.5 million through equity financing, ending Q1 2021 with $33.1 million in cash. Revenue increased 32% year-over-year to $222,000, while R&D expenses decreased 19% to $820,000. However, selling, general, and administrative expenses surged by 46% to $1.2 million, largely due to merger-related costs of $2.1 million. The firm aims to leverage induced pluripotent stem cell technology for drug discovery, focusing on Rett Syndrome and CDKL5.
Vyant Bio (Nasdaq: VYNT) will host an investor conference call on May 18, 2021, at 8:30 AM ET, to discuss Q1 2021 milestones. CEO Jay Roberts and CFO Andy LaFrence will highlight achievements and future financial plans. The live event will also be recorded for later access. Vyant Bio focuses on drug discovery through advanced biotechnology, using data and regulatory expertise. The company has changed its name from Cancer Genetics, Inc. earlier in March 2021, and operates two subsidiaries: StemoniX and vivoPharm.
Vyant Bio, Inc. (Nasdaq: VYNT) announced that CEO Jay Roberts will present at the BioNJ’s 11th Annual BioPartnering Conference from May 17-21, 2021, with his presentation scheduled for May 18. The conference aims to showcase the company's updated business strategy post-merger with StemoniX, emphasizing partnerships and innovative drug discovery. The session will be available on-demand for registered guests from May 18 to June 25, 2021. This conference highlights Vyant Bio's focus on integrating human biology and data science in therapeutic discovery.
Vyant Bio (Nasdaq: VYNT) announces a collaboration with Ordaōs Bio and Cellaria to enhance drug discovery. This partnership will utilize artificial intelligence and in vitro 'avatar' clinical trials to streamline therapeutic design and development, focusing on small protein therapeutics. By leveraging patient-specific models and AI-generated protein sequences, the initiative aims to optimize drug efficacy evaluations before clinical trials. This strategy targets diseases such as cancer and pancreatic disorders, potentially transforming the drug development landscape.
On April 5, 2021, Vyant Bio (Nasdaq: VYNT) announced the formation of a new Board of Directors with extensive experience in drug discovery and development. The board aims to drive innovation and growth, integrating its two subsidiaries, StemoniX and vivoPharm. The new members include industry leaders such as John Fletcher and Joanna Horobin, enhancing Vyant Bio's strategic direction. The company will hold an investor conference call on April 6, 2021, to discuss these developments further.
Vyant Bio, Inc. (Nasdaq: VYNT) announced an investor webcast on April 6, 2021, to discuss corporate and operational updates following its merger with StemoniX, Inc. CEO Jay Roberts will lead the discussion, joined by key executives. The webcast aims to provide insights into the company’s drug discovery advancements and integration of human-powered scientific systems. Vyant Bio integrates expertise from its subsidiaries, StemoniX and vivoPharm, to enhance drug development processes and outcomes.